In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $0.7 up 3.77% from its previous closing price of $0.67. In other words, the price has increased by $3.77 from its previous closing price. On the day, 4.92 million shares were traded. SGMO stock price reached its highest trading level at $0.7297 during the session, while it also had its lowest trading level at $0.646.
Ratios:
For a deeper understanding of Sangamo Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.05 and its Current Ratio is at 1.05. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.20.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 211196624 and an Enterprise Value of 196313632. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.58 while its Price-to-Book (P/B) ratio in mrq is 9.74. Its current Enterprise Value per Revenue stands at 2.403 whereas that against EBITDA is -3.369.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.27, which has changed by -0.1025641 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 26.07%, while the 200-Day Moving Average is calculated to be -14.78%.
Shares Statistics:
For the past three months, SGMO has traded an average of 5.70M shares per day and 6603370 over the past ten days. A total of 301.71M shares are outstanding, with a floating share count of 291.68M. Insiders hold about 3.32% of the company’s shares, while institutions hold 17.09% stake in the company. Shares short for SGMO as of 1757894400 were 17678359 with a Short Ratio of 3.10, compared to 1755216000 on 15958387. Therefore, it implies a Short% of Shares Outstanding of 17678359 and a Short% of Float of 5.91.
Earnings Estimates
The stock of Sangamo Therapeutics Inc (SGMO) is currently drawing attention from 3 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.37 and -$0.43 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.3, with 3.0 analysts recommending between -$0.12 and -$0.4.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $34.4M this quarter.It ranges from a high estimate of $100M to a low estimate of $4M. As of. The current estimate, Sangamo Therapeutics Inc’s year-ago sales were $49.41M
A total of 5 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $124.7M, while the lowest revenue estimate was $34.7M, resulting in an average revenue estimate of $72.3M. In the same quarter a year ago, actual revenue was $57.8MBased on 5 analysts’ estimates, the company’s revenue will be $48.3M in the next fiscal year. The high estimate is $114.2M and the low estimate is $8.6M.
